NeoGenomics Inc (NEO)
16.87
-1.29
(-7.10%)
USD |
NASDAQ |
Mar 24, 16:00
17.21
+0.34
(+2.02%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.150B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -5.44% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.111 |
| Price to Book Value | 2.154 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5364 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 89.23% |
News
Headline
Wire
Time (ET)
MT Newswires
03/22 11:08
Yahoo
03/22 08:00
NeoGenomics' (NASDAQ:NEO) growing losses don't faze investors as the stock grows 4.7% this past week
Yahoo
03/21 08:06
Globe Newswire
03/17 17:00
Accesswire
03/16 07:00
Yahoo
03/13 07:00
MT Newswires
03/03 11:10
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 04/27/2023* | 08:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 04/27/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 02/23/2023 | 08:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/23/2023 | -- | Results | Q4 2022 | -0.06 | -0.16 | 63.55% | |
| 11/08/2022 | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/08/2022 | -- | Results | Q3 2022 | -0.14 | -0.21 | 32.09% | |
| 08/09/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/09/2022 | -- | Results | Q2 2022 | -0.16 | -0.23 | 29.01% |
*Estimated Date/Time
Earnings
Profile
Edit
| NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services. |
| URL | https://www.neogenomics.com |
| Investor Relations URL | https://ir.neogenomics.com/ |
| HQ State/Province | Florida |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Apr. 27, 2023 (est.) |
| Last Earnings Release | Feb. 23, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 24, 2023.
Fundamentals
| Revenue (TTM) | 509.73M |
| Total Expenses (TTM) | 662.84M |
| Net Income (TTM) | -144.25M |
| Total Assets (Quarterly) | 1.740B |
| Total Liabilities (Quarterly) | 742.01M |
| Shareholders Equity (Quarterly) | 998.02M |
| Cash from Operations (TTM) | -65.99M |
| Cash from Investing (TTM) | 0.517M |
| Cash from Financing (TTM) | 11.83M |
Ratings
Profile
Edit
| NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services. |
| URL | https://www.neogenomics.com |
| Investor Relations URL | https://ir.neogenomics.com/ |
| HQ State/Province | Florida |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Apr. 27, 2023 (est.) |
| Last Earnings Release | Feb. 23, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| NEO Tweets |